104 related articles for article (PubMed ID: 7857701)
1. In vivo stimulation by tamoxifen of cathepsin D RNA level in breast cancer.
Maudelonde T; Escot C; Pujol P; Rouanet P; Defrenne A; Brouillet JP; Rochefort H
Eur J Cancer; 1994; 30A(14):2049-53. PubMed ID: 7857701
[TBL] [Abstract][Full Text] [Related]
2. Cathepsin D, both a prognostic factor and a predictive factor for the effect of adjuvant tamoxifen in breast cancer. South Sweden Breast Cancer Group.
Fernö M; Baldetorp B; Borg A; Brouillet JP; Olsson H; Rochefort H; Sellberg G; Sigurdsson H; Killander D
Eur J Cancer; 1994; 30A(14):2042-8. PubMed ID: 7857700
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen treatment increases the concentration of 52K-cathepsin D and its precursor in breast cancer tissue.
Maudelonde T; Domergue J; Henquel C; Freiss G; Brouillet JP; Simony J; Pujol H; Rochefort H
Cancer; 1989 Apr; 63(7):1265-70. PubMed ID: 2920355
[TBL] [Abstract][Full Text] [Related]
4. Oestrogenic activity of tamoxifen and its metabolites on gene regulation and cell proliferation in MCF-7 breast cancer cells.
Johnson MD; Westley BR; May FE
Br J Cancer; 1989 May; 59(5):727-38. PubMed ID: 2736207
[TBL] [Abstract][Full Text] [Related]
5. The role of cathepsin D and PAI-1 in primary invasive breast cancer as prognosticators and predictors of treatment benefit with adjuvant tamoxifen.
Billgren AM; Rutqvist LE; Johansson H; Hägerström T; Skoog L
Eur J Cancer; 2000 Jul; 36(11):1374-80. PubMed ID: 10899650
[TBL] [Abstract][Full Text] [Related]
6. Expression of the oestrogen regulated pNR-2 mRNA in human breast cancer: relation to oestrogen receptor mRNA levels and response to tamoxifen therapy.
Henry JA; Nicholson S; Hennessy C; Lennard TW; May FE; Westley BR
Br J Cancer; 1990 Jan; 61(1):32-8. PubMed ID: 2153395
[TBL] [Abstract][Full Text] [Related]
7. Correlation between mannose-6-phosphate/IGFII receptor and cathepsin D RNA levels by in situ hybridization in benign and malignant mammary tumors.
Zhao Y; Escot C; Maudelonde T; Puech C; Rouanet P; Rochefort H
Cancer Res; 1993 Jun; 53(12):2901-5. PubMed ID: 7684951
[TBL] [Abstract][Full Text] [Related]
8. Steroid receptors, pS2 and cathepsin D in early clinically node-negative breast cancer.
Stonelake PS; Baker PG; Gillespie WM; Dunn JA; Spooner D; Morrison JM; Bundred NJ; Oates GD; Lee MJ; Neoptolemos JP
Eur J Cancer; 1994; 30A(1):5-11. PubMed ID: 8142164
[TBL] [Abstract][Full Text] [Related]
9. Immunoradiometric detection of pS2 and total cathepsin D in primary breast cancer biopsies: their correlation with steroid receptors.
Marsigliante S; Biscozzo L; Correale M; Paradiso A; Leo G; Abbate I; Dragone CD; Storelli C
Br J Cancer; 1994 Mar; 69(3):550-4. PubMed ID: 8123486
[TBL] [Abstract][Full Text] [Related]
10. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO
Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399
[TBL] [Abstract][Full Text] [Related]
11. Oestrogen regulates cathepsin D mRNA levels in oestrogen responsive human breast cancer cells.
Westley BR; May FE
Nucleic Acids Res; 1987 May; 15(9):3773-86. PubMed ID: 3588310
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet; 1998 May; 351(9114):1451-67. PubMed ID: 9605801
[TBL] [Abstract][Full Text] [Related]
13. Decrease of c-erbB-2 and c-myc RNA levels in tamoxifen-treated breast cancer.
Le Roy X; Escot C; Brouillet JP; Theillet C; Maudelonde T; Simony-Lafontaine J; Pujol H; Rochefort H
Oncogene; 1991 Mar; 6(3):431-7. PubMed ID: 1707153
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer.
Swain SM; Wilson JW; Mamounas EP; Bryant J; Wickerham DL; Fisher B; Paik S; Wolmark N
J Natl Cancer Inst; 2004 Apr; 96(7):516-23. PubMed ID: 15069113
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
[TBL] [Abstract][Full Text] [Related]
16. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
17. Cathepsin D in breast cancer.
Rochefort H
Breast Cancer Res Treat; 1990 Jul; 16(1):3-13. PubMed ID: 2207345
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of the estrogen-regulated protein, cathepsin D, in breast cancer. An immunohistochemical study.
Henry JA; McCarthy AL; Angus B; Westley BR; May FE; Nicholson S; Cairns J; Harris AL; Horne CH
Cancer; 1990 Jan; 65(2):265-71. PubMed ID: 2295049
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen induces heparanase expression in estrogen receptor-positive breast cancer.
Cohen I; Maly B; Simon I; Meirovitz A; Pikarsky E; Zcharia E; Peretz T; Vlodavsky I; Elkin M
Clin Cancer Res; 2007 Jul; 13(14):4069-77. PubMed ID: 17634531
[TBL] [Abstract][Full Text] [Related]
20. Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status.
Clarke RB; Laidlaw IJ; Jones LJ; Howell A; Anderson E
Br J Cancer; 1993 Mar; 67(3):606-11. PubMed ID: 8439511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
